A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Hyeon | - |
dc.contributor.author | Park, Jung Min | - |
dc.contributor.author | Jung, Eunsun | - |
dc.contributor.author | Lee, Jieun | - |
dc.contributor.author | Han, Jiyou | - |
dc.contributor.author | Kim, Yoon-Jae | - |
dc.contributor.author | Kim, Ji Young | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2022-10-04T02:40:13Z | - |
dc.date.available | 2022-10-04T02:40:13Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.issn | 1878-5905 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61522 | - |
dc.description.abstract | Cancer stem-like cells (CSCs) represent a key barrier to successful therapy for triple-negative breast cancer (TNBC). CSCs promote the emergence of chemoresistance, triggering relapse and resulting in a poor prognosis. We herein present CDF-TM, a new small molecule-based binary prodrug conjugated with SN-38 and 3,4-difluorobenzylidene curcumin (CDF) that is specifically activated in hypoxic conditions. CDF-TM treatment significantly induced apoptosis in TNBC-derived 3D spheroids, accompanied with caspase-3 activation as well as the attenuation of tumor stemness with evidence of reduction in aldehyde dehydrogenase 1 (ALDH1) activity and the CD44high/CD24low phenotype. An in vivo orthotopic allograft model was used to investigate its effects on tumor growth and metastasis. The dissemination of CSCs from primary allografts was impaired by CDF-TM, along with inhibition of tumor growth via eradication of CSCs and downregulation of multidrug resistance 1 (MDR1). This new small molecule-based binary prodrug offers a novel therapeutic option for metastatic TNBC. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.title | A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.biomaterials.2022.121781 | - |
dc.identifier.scopusid | 2-s2.0-85138095706 | - |
dc.identifier.wosid | 000855418200001 | - |
dc.identifier.bibliographicCitation | Biomaterials, v.289 | - |
dc.citation.title | Biomaterials | - |
dc.citation.volume | 289 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | NEGATIVE BREAST-CANCER | - |
dc.subject.keywordPlus | ADP-RIBOSE POLYMERASE | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANCE | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN | - |
dc.subject.keywordPlus | HYPOXIA | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PHENOTYPE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SYSTEMS | - |
dc.subject.keywordAuthor | Triple-negative breast cancer | - |
dc.subject.keywordAuthor | Cancer stem cells | - |
dc.subject.keywordAuthor | MDR1 | - |
dc.subject.keywordAuthor | Binary prodrug | - |
dc.subject.keywordAuthor | Metastasis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.